Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Candesartan cilexetil; hydrochlorothiazide

Candesartan cilexetil; hydrochlorothiazide: 1 brand, 6 generics; first approved Sep 05, 2000; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 6 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
6
Listed patents
0
Presentations
21

Brand (NDA) products

Originator applications
Ask AI
  • NDA 02109320003 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALRxAB
    32MG;25MGTABLETORALRxAB

Generic (ANDA) products (6)

Abbreviated applications
Ask AI
  • ANDA 20745520183 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALRxAB
    32MG;25MGTABLETORALRxAB
  • ANDA 20346620173 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALRxAB
    32MG;25MGTABLETORALRxAB
  • ANDA 20410020153 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALRxAB
    32MG;25MGTABLETORALRxAB
  • ANDA 20296520133 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALRxAB
    32MG;25MGTABLETORALRxAB
  • ANDA 20288420123 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALDiscontinued-
    32MG;12.5MGTABLETORALDiscontinued-
    32MG;25MGTABLETORALDiscontinued-
  • ANDA 09070420123 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    16MG;12.5MGTABLETORALRxAB
    32MG;12.5MGTABLETORALDiscontinued-
    32MG;25MGTABLETORALRxAB

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
Ask AI
First approval
26 yr 7 mo ago
Most recent approval
8 yr 9 mo ago

Approvals span 2000–2018 across 7 FDA applications.

Brand (NDA) 114%
Generic (ANDA) 686%

Candesartan cilexetil; hydrochlorothiazide: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Candesartan cilexetil; hydrochlorothiazide

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo